Retinopathy of Prematurity - Roger Johnson Ophthalmology Lecture
Objectives and Disclosures
Participants will be able to:
- assess and apply changes to the classification of ROP
- evaluate an infant’s risk for severe ROP
- compare the advantages and disadvantages of different treatment modalities for ROP.
Planners and disclose they have no relevant financial relationships. Speaker intends to reference the off-label use of anti-VEGF medications for the treatment of ROP. Speaker discloses: Consultant and stockholder with Luminopia; ownership in X Biomedical All relevant financial relationships have been mitigated.
Gil Binenbaum, MD, MSCE
Chief of Ophthalmology, Children's Hospital of Philadelphia; Director of Research, Ophthalmology, Ophthalmology Core Medical Director, Clinical and Translational Research Center Associate Professor of Ophthalmology, Perelman School of Medicine at the University of Pennsylvania
Seattle Children’s is accredited by the Washington State Medical Association CME Accreditation Committee to sponsor continuing medical education for physicians.
Seattle Children’s designates this online educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 1 hour of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Videos are available for only one year after posting.
If you wish to receive Category I CME credit for viewing this Provider Grand Rounds session, please complete the evaluation form. Upon completion of the form you will receive an auto-reply email that will serve as the only confirmation of your CME credit. Please keep the email for your records.